Health Care International - TREDAPTIVETM (Nicotinic Acid /Laropiprant) Approved In The European Union: New Lipid-Modifying Therapy To Treat LDL-C, HDL-C And Triglycerides
Merck Sharp & Dohme (MSD) announced that TREDAPTIVEā¢ (nicotinic acid/laropiprant, MSD) 1 g/20 mg modified-release tablets, a new lipid-modifying therapy for patients with dyslipidemia and primary hypercholesterolemia, has been approved for marketing
Comments